Figures & data
Table 1 Baseline characteristics
Figure 1 The CHADS2 (A), CHA2DS2-VASc (B), and HAS-BLED (C) score histograms. More than 80% patients had a CHADS2/CHA2DS2-VASc ≥2. The CHADS2 (D) and HAS-BLED scores (E) increased with age.
Figure 2 Differences in the antithrombotic strategy for stroke prevention according to the CHADS2 score (A) and CHA2DS2-VASc score (B) between the secondary and tertiary hospitals. For patients with CHADS2 ≥2, the OAC use rate in the secondary hospitals was significantly lower than the rate in the tertiary hospitals (P<0.001). The distribution of antithrombotic drugs according to the CHADS2 scores (C) showed that the proportion of anticoagulant therapy did not increase with the CHADS2 score. Antithrombotic drug use in the different age groups (D) showed that OAC was rarely prescribed to the elderly patients. Others indicate clopidogrel, cilostazol, low-molecular weight heparin, and fondaparinux sodium; secondary H. indicates the secondary hospitals; and tertiary H. indicates the tertiary hospitals.
Table 2 NVAF patients in secondary hospitals vs. NVAF patients in tertiary hospitals
Table 3 Main reasons why warfarin was not prescribed to NVAF patients with CHADS2 ≥2